Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesCynata Therapeutics Ltd

Cynata Therapeutics Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.012 AUD -0.00 ( 7.69%)
Last update at 2026-11-06T05:10:00Z
VOLUME
323065
Market Cap
4.38M

Momentum Score

…

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.43
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cynata Therapeutics is an Australian clinical-stage regenerative medicine company developing allogeneic mesenchymal stem cell therapies using its Cymerus platform derived from induced pluripotent stem cells. Long-term growth drivers include the platform's potential for scalable, off-the-shelf manufacturing, progress in clinical programs targeting unmet needs in inflammatory and degenerative diseases, and opportunities for partnerships or licensing that could support commercial development.
Principal risks include clinical and regulatory failure, limited commercial revenue and ongoing financing needs, competition from other cell-therapy developers, and potential manufacturing or intellectual property challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
1.71M
Revenue Per Share
0.01
Gross Profit TTM
1.71M
Debt / Equity
-
ROE
-340.78%
Net Debt
-0.90M
ROCE
2416.49%
Diluted EPS TTM
-0.04

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -9.09M -9.39M -12.06M -14.28M -5.45M
Net income -9.09M -9.39M -9.74M -14.28M -5.45M
Selling general administrative - 3.40M 3.21M 3.18M 3.99M
Selling and marketing expenses - - - 0.06M 0.07M
Gross profit - 1.89M 2.32M 1.65M 7.77M
Reconciled depreciation - 0.28M 0.28M 0.28M 0.28M
Ebit - -9.61M -10.23M -16.54M -13.84M
Ebitda -9.53M -9.33M -9.95M -16.26M -13.56M
Depreciation and amortization - 0.28M 0.28M 0.28M 0.28M
Operating income -9.53M -8.12M -8.81M -14.89M -6.07M
Other operating expenses 9.53M 10.01M 11.12M -16.28M -13.28M
Interest expense - - - - 0.06M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.23M 0.42M 0.26M 0.06M
Net interest income - 0.23M 0.42M 0.35M 0.06M
Income tax expense - -1.89M -2.32M -0.35M -0.06M
Total revenue - 1.89M 2.32M 1.65M 7.77M
Total operating expenses 9.53M 10.01M 11.12M 16.54M 13.84M
Cost of revenue - - 0.28M - -
Total other income expense net 0.44M -1.27M -3.25M 1.91M 8.33M
Net income from continuing ops - -9.39M -9.74M -14.28M -5.45M
Net income applicable to common shares - -9.39M -9.74M -14.28M -5.45M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 1.35M 7.20M 8.39M 18.99M 26.55M
Intangible assets - 1.85M - 2.13M 2.41M
Other current assets 0.15M - 0.22M 0.03M 0.24M
Total liab 1.75M 1.22M 1.17M 2.26M 2.59M
Total stockholder equity -0.39M 5.98M 7.22M 16.73M 23.96M
Deferred long term liab - - - 2.13M 2.41M
Other current liab 0.73M - 0.74M 0.95M 1.01M
Common stock - - 81.62M 81.62M 74.90M
Capital stock - 89.52M - 81.62M 74.90M
Retained earnings -100.80M -91.71M -82.32M -72.57M -58.30M
Other assets - - 0.00M 2.13M 2.41M
Cash 0.90M 5.05M 6.21M 16.17M 23.80M
Total current liabilities 1.75M 1.22M 1.17M 2.26M 2.59M
Net debt -0.90M - -6.21M -16.17M -23.80M
Short term debt - - - 0.00M 0.00M
Other stockholder equity 100.40M - - -9.05M -16.60M
Total current assets 1.12M 5.35M 6.54M 16.86M 24.14M
Net tangible assets - - - 16.73M 23.96M
Short term investments - - - 0.03M 0.03M
Net receivables 0.07M - 0.11M 0.37M 0.10M
Accounts payable 1.02M 0.39M 0.43M 1.31M 1.58M
Accumulated other comprehensive income - - 7.91M 7.68M 7.36M
Non current assets total 0.23M 1.85M 1.85M 2.13M 2.41M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.05M - - -
Change to liabilities - - - -0.26M 0.95M
Total cashflows from investing activities - -0.05M - - -
Total cash from financing activities 2.58M 7.61M 0.00M 6.72M 0.21M
Change to operating activities - - - -0.07M 0.03M
Net income -9.09M -9.39M -9.74M -14.28M -5.45M
Change in cash -4.15M -1.16M -9.96M -7.63M -2.92M
Begin period cash flow 5.05M 6.21M 16.17M 23.80M 26.72M
End period cash flow 0.90M 5.05M 6.21M 16.17M 23.80M
Total cash from operating activities -6.74M -8.72M -9.96M -14.28M -3.30M
Issuance of capital stock - 8.14M - 7.04M -
Depreciation 0.26M - 0.28M 0.28M 0.28M
Change to account receivables - 0.03M 0.36M -0.36M 0.02M
Sale purchase of stock - -0.52M 0.00M -0.32M -0.32M
Other cashflows from financing activities 2.58M -0.52M 0.00M -0.32M 0.21M
Change to netincome - - - 0.40M 0.86M
Capital expenditures 0.00M 0.05M 0.00M 0.00M 0.00M
Change in working capital - 0.13M -0.73M -0.36M 0.02M
Stock based compensation 0.13M - 0.23M 0.33M 1.03M
Other non cash items 1.96M -8.85M 0.51M -0.29M 1.87M
Free cash flow -6.74M -8.77M -9.96M -14.28M -3.30M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CYP
Cynata Therapeutics Ltd		 -0.00
7.69%		 0.01 - - 2.56 0.75 596.98 -1.73
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Cynata Therapeutics Ltd

Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.

100 Cubitt Street, Cremorne, VIC, Australia, 3121

61 3 7067 6940

https://cynata.com

Name Title Year Born
Dr. Ross Alexander MacDonald Ph.D. MD, CEO & Exec. Director 1958
Dr. Kilian Kelly Chief Operating Officer NA
Dr. Jolanta Airey Chief Medical Officer NA
Dr. Suzanne Lipe VP of Alliance Management 1950
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D., MAICD Company Sec. 1963
Dr. Kilian Kelly MD, CEO & Director NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963
Dr. Kilian Kelly MD, CEO & Director NA
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary 1963
Dr. Kilian Kelly MD, CEO & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…